New Zealand: Dechra seeks clearance to acquire Osurnia from ElancoChristian Fernsby ▼ | April 3, 2020
The Commission has received a clearance application from Dechra Pharmaceuticals PLC, Dechra Limited and Dechra Veterinary Products LLC seeking clearance to acquire from Elanco Tiergesundheit AG its worldwide assets, rights and liabilities relating to Osurnia, a treatment for otitis in dogs.
Animal healthcare Dechra Pharmaceuticals
Topics: New Zealand Dechra acquire Osurnia Elanco
Elanco also develops, manufactures and distributes healthcare treatments for a range of different companion and production animals on a global basis.
In New Zealand, Dechra and Elanco overlap in the supply of products used in the treatment of otitis in dogs. Otitis is an inflammation of the external ear canal and it is a common affliction in dogs.
The Commission is currently considering an application from Elanco, which is seeking clearance to acquire Bayer AG’s animal health business which includes a treatment for otitis in dogs. They will consider the two applications in tandem. ■